IRVINE, CA. -- Edwards Lifesciences Corporation, the global leader in the science of heart valves and hemodynamic monitoring, today announced it has received CE Mark in Europe for valve-in-valve ...

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of ...

PARIS., Edwards Lifesciences Corporation, the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that 30-day data from its European ...

Edwards Lifesciences Corp. won FDA approval for its Sapien 3 transcatheter heart valve device for aortic and mitral valve-in-valve procedures. The Irvine, Calif.-based company leads the way in a ...

August 18, 2010 (Montreal, Quebec and Leicester, United Kingdom) — The best way to ensure that a patient who meets criteria for undergoing transcatheter aortic-valve replacement actually ends up ...

Hoag Memorial Hospital Presbyterian in Newport Beach will be among one of the first U.S. hospitals to offer a much-touted medical device from a device maker here. Irvine-based Edwards Lifesciences ...

IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced the company’s SAPIEN M3 mitral valve replacement system is the first transcatheter therapy utilizing a transseptal approach ...

NYON, Switzerland--(BUSINESS WIRE)--Edwards Lifesciences today announced the launch in Europe of the SAPIEN 3 transcatheter pulmonary valve implantation (TPVI) system with Alterra adaptive prestent, ...

SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The ...

The FDA approved a new version of Edwards Lifesciences’ Sapien 3 transcatheter heart valve—coupling it with a self-expanding, stent-like device that helps reshape a malfunctioning pulmonary valve.